Landmark Bio News and Resources

Landmark Bio has been acquired by Artis BioSolutions (“Artis”), a newly launched company focused on streamlining the discovery, process development, and manufacturing of genetic medicines. The acquisition will allow Landmark Bio to expand its capabilities and continue its mission of translating groundbreaking research

ChromaTan Inc. and Landmark Bio PBLLC have been awarded a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to advance recombinant adeno-associated virus (AAV) production. The funding supports NIIMBL’s Viral Vector Manufacturing and Analytics Program, aiming to enhance biopharmaceutical manufacturing